



Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery

Results of a randomized, double-blind, controlled study

E. R. Viscusi,¹ S. Goldstein,¹ T. Witkowski,¹ A. Andonakakis,¹ R. Jan,¹ K. Gabriel,¹ W. Du,² L. Techner,² B. Wallin²

¹ Jefferson Medical College, Thomas Jefferson University, 111 South 11th Street, Suite G8490, Philadelphia, PA 19107-5092, USA

² Adolor Corporation, Exton, PA, USA

[Surg Endosc (2006) 20: 64–70, DOI: 10.1007/s00464-005-0104-y]

On page 65, in column 1 of the “Patients and methods” section, the wrong study number was published. The first sentence under the heading “Study design and treatments” should read:

This was a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (Study 14CL308) designed to evaluate the efficacy and safety of 6 and 12 mg alvimopan for the management of POI in patients undergoing BR or TAH.